Parathormone levels add prognostic ability to N‐terminal pro‐brain natriuretic peptide in stable coronary patients

There are controversial data on the ability of the components of mineral metabolism (vitamin D, phosphate, parathormone [PTH], fibroblast growth factor‐23 [FGF23], and klotho) to predict cardiovascular events. In addition, it is unknown whether they add any prognostic value to other well‐known biomarkers.

[1]  M. Szklo,et al.  Impact of race on the association of mineral metabolism with heart failure: the Multi-Ethnic Study of Atherosclerosis. , 2019, The Journal of clinical endocrinology and metabolism.

[2]  J. Manson,et al.  Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease , 2019, The New England journal of medicine.

[3]  F. Rodríguez‐Artalejo,et al.  Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate , 2016, Journal of Bone and Mineral Metabolism.

[4]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[5]  S. Plein,et al.  Effects of Vitamin D on Cardiac Function in Patients With Chronic HF , 2016, Journal of the American College of Cardiology.

[6]  M. M. Joosten,et al.  Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study , 2016, ESC heart failure.

[7]  Y. Alsancak,et al.  Association between parathyroid hormone levels and the extensiveness of coronary artery disease , 2016, Anatolian journal of cardiology.

[8]  Bo Yang,et al.  Parathyroid hormone, cardiovascular and all-cause mortality: A meta-analysis. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[9]  W. März,et al.  Soluble klotho and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. , 2015, Atherosclerosis.

[10]  H. Malluche,et al.  High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis. , 2015, Journal of the American Society of Nephrology : JASN.

[11]  B. Kestenbaum,et al.  Serum Parathyroid Hormone and 25‐Hydroxyvitamin D Concentrations and Risk of Incident Heart Failure: The Multi‐Ethnic Study of Atherosclerosis , 2014, Journal of the American Heart Association.

[12]  P. Whincup,et al.  Elevated Parathyroid Hormone, But Not Vitamin D Deficiency, Is Associated With Increased Risk of Heart Failure in Older Men With and Without Cardiovascular Disease , 2014, Circulation. Heart failure.

[13]  J. Pankow,et al.  Parathyroid hormone concentration and risk of cardiovascular diseases: the Atherosclerosis Risk in Communities (ARIC) study. , 2014, American heart journal.

[14]  D. Fliser,et al.  Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[15]  F. Rodríguez‐Artalejo,et al.  Coexistence of Low Vitamin D and High Fibroblast Growth Factor-23 Plasma Levels Predicts an Adverse Outcome in Patients with Coronary Artery Disease , 2014, PloS one.

[16]  J. Egido,et al.  Parathormone levels are independently associated with the presence of left ventricular hypertrophy in patients with coronary artery disease , 2015, The journal of nutrition, health & aging.

[17]  F. Rodríguez‐Artalejo,et al.  Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. , 2014, The American journal of cardiology.

[18]  M. Visser,et al.  Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. , 2013, American heart journal.

[19]  A. Ortiz,et al.  Vitamin D receptor activation and cardiovascular disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  B. Nordestgaard,et al.  25-Hydroxyvitamin D Levels and Risk of Ischemic Heart Disease, Myocardial Infarction, and Early Death: Population-Based Study and Meta-Analyses of 18 and 17 Studies , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[21]  M. Pelizzo,et al.  Coronary Microvascular Dysfunction Induced by Primary Hyperparathyroidism is Restored After Parathyroidectomy , 2012, Circulation.

[22]  N. Fujii,et al.  Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[23]  S. Solomon,et al.  Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. , 2012, JAMA.

[24]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[25]  B. Kestenbaum,et al.  Vitamin D, parathyroid hormone, and cardiovascular events among older adults. , 2011, Journal of the American College of Cardiology.

[26]  B. Horne,et al.  Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? , 2011, American heart journal.

[27]  A. Hayen,et al.  Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. , 2011, JAMA.

[28]  W. März,et al.  Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. , 2010, European heart journal.

[29]  L. Schurgers,et al.  The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.

[30]  G. Curhan,et al.  Parathyroid hormone and the risk of incident hypertension , 2008, Journal of hypertension.

[31]  Stefan Pilz,et al.  Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. , 2008, Archives of internal medicine.

[32]  Sharon M Moe,et al.  Mechanisms of vascular calcification in chronic kidney disease. , 2008, Journal of the American Society of Nephrology : JASN.

[33]  F. Kronenberg,et al.  Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. , 2007, Journal of the American Society of Nephrology : JASN.

[34]  Animesh Nandi,et al.  Suppression of Aging in Mice by the Hormone Klotho , 2005, Science.

[35]  S. Kato,et al.  Role of the vitamin D receptor in FGF23 action on phosphate metabolism. , 2005, The Biochemical journal.

[36]  J. Sundsfjord,et al.  Serum parathyroid hormone levels predict coronary heart disease: the Tromsø Study , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[37]  Tadashi Kaname,et al.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing , 1997, Nature.

[38]  K. Schlüter,et al.  Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. , 1992, The American journal of physiology.

[39]  R. Beaglehole,et al.  Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. , 1990, International journal of epidemiology.

[40]  S. Plein,et al.  Effects of Vitamin D on Cardiac Function in Patients With Chronic HF The VINDICATE Study , 2016 .

[41]  G. Yang,et al.  Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD , 2014, Osteoporosis International.

[42]  S. Mundra,et al.  Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis , 2009 .